skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Ropinirole for the treatment of restless legs syndrome

(2177) Views  (413) Full article downloads

Authors: Clete A Kushida

Published Date February 2006 Volume 2006:2(4) Pages 407 - 419
DOI: http://dx.doi.org/10.2147/NDT.S

Clete A Kushida

Stanford University Center of Excellence for Sleep Disorders, Stanford, CA, USA

Abstract: Dopaminergic agents, anticonvulsants, benzodiazepines, opiates, and iron supplementation comprise the classes of medications commonly used to treat restless legs syndrome (RLS), which is a disorder that is estimated to affect about 1 in 10 individuals worldwide and impacts an affected patient’s sleep, mood, daytime function, and quality of life. RLS is characterized by an urge to move the legs that is worse at bedtime and at rest; the symptoms are temporarily relieved by leg movement. It is frequently accompanied by periodic limb movements during sleep (PLMS), which may independently disrupt sleep and may cause daytime drowsiness. Dopaminergic agents are considered to be first-line therapy in the management of RLS as well as PLMS. Ropinirole (Requip®, GlaxoSmithKline) is a dopamine agonist that was the first medication approved by the US Food and Drug Administration (FDA) for the treatment of moderate-to-severe primary RLS. Based on several large-scale clinical trials and open-label clinical series, this medication has been demonstrated to be effective and safe in treating the motor symptoms of RLS and improving sleep quality.

Keywords: ropinirole, restless legs syndrome, RLS, periodic limb movements








Readers of this article also read:

Rotigotine transdermal system: a short review
A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder
Atomoxetine: a novel treatment for child and adult ADHD
Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics
Editorial: Restless legs is a medical disorder and can be treated ||FREE PAPER||
Update on ropinirole in the treatment of Parkinson’s disease
Ropinirole in restless legs syndrome and periodic limb movement disorder
Trazodone effects on [3H]-paroxetine and α2-adrenoreceptors in platelets of patients with major depression
Evaluating the effects of crystallinity in new biocompatible polyester nanocarriers on drug release behavior
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies